Skip to main content Accessibility help
×
Hostname: page-component-7bb8b95d7b-nptnm Total loading time: 0 Render date: 2024-10-05T00:34:30.372Z Has data issue: false hasContentIssue false

10 - Receptor Imaging

Published online by Cambridge University Press:  22 November 2017

Michael Graham
Affiliation:
Department of Radiology, University of Iowa, Iowa City, IA
Hossein Jadvar
Affiliation:
University of Southern California Keck School of Medicine, Los Angeles
Heather Jacene
Affiliation:
Dana-Farber Cancer Institute, Boston
Michael Graham
Affiliation:
University of Iowa
Get access

Summary

Cell surface receptors and their associated receptor ligands are fundamental and essential aspects of the physiology and homeostasis of virtually all multi-cellular organisms. In addition, many tumors have either unique receptors or have significantly up-regulated receptors that can be exploited for both diagnosis and therapy. There are currently several approved radiopharmaceuticals that are available, as well as a major amount of research going into the development of new receptor-based imaging agents. The currently available agents are listed in Table 10.1.

The obvious key approach for receptor imaging is to identify a ligand that binds to the receptor and that can be imaged. This usually involves an imaging entity, a linker, and the binding ligand, see Figure 10.1.

There are several considerations that must be taken into account in the selection of specific ligands, linkers, and labels for different situations. Some of the most important general considerations in selecting a specific combination are metabolic stability, in-vivo pharmacokinetics, and imaging label characteristics. The combined imaging agent must be metabolically stable, so that the label remains attached to the ligand. The ligand should have high receptor specificity and affinity, so that it binds to the desired receptor well and does not bind significantly elsewhere. The label should have a half-life that is compatible with the rate that the ligand binds to the receptor and clears from the background. Other considerations are discussed in the pages that follow.

Receptor Ligands

Oligopeptide Ligands

Since every receptor has to have a binding ligand, the most direct approach is to identify the endogenous or exogenous binding protein and use it in the design of a receptor imaging agent. Generally, this direct approach is not successful because of the relatively rapid metabolic degradation of endogenous ligands. For instance, somatostatin has a half-life in the circulation of only 2–3 minutes. The usual approach is to modify the endogenous ligand to decrease or block its metabolism, but at the same time preserve the receptor affinity. This approach has been used successfully for the somatostatin receptor, which can be imaged with In-111 pentetreotide. The label is In-111, the linker is di-ethylene-triamine-penta-acetic (DTPA), and the ligand is an oligopeptide consisting of eight amino acids similar to the binding part of somatostatin.

Type
Chapter
Information
Molecular Imaging
An Introduction
, pp. 43 - 46
Publisher: Cambridge University Press
Print publication year: 2017

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bigott-Hennkens, HM, Dannoon S, Lewis MR, Jurisson SS. In vitro receptor binding assays: general methods and considerations. Q J Nucl Med Mol Imaging. 2008 Sep;52(3):245–53.Google ScholarPubMed
Ellington, AD, Szostak, JW. In vitro selection of RNA molecules that bind specific ligands. Nature. 1990 Aug 30;346(6287):818–22.CrossRefGoogle ScholarPubMed
Innis, RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007 Sep;27(9):1533–9.CrossRefGoogle ScholarPubMed
Krohn, KA, Link, JM. Interpreting enzyme and receptor kinetics: keeping it simple, but not too simple. Nucl Med Biol. 2003 Nov;30(8):819–26.CrossRefGoogle Scholar
Mankoff, DA, Link JM, Linden HM, Sundararajan L, Krohn KA. Tumor receptor imaging. J Nucl Med. 2008 Jun;49 Suppl 2:149S–63S.CrossRefGoogle ScholarPubMed
Mohanty, C, Das M, Kanwar JR, Sahoo SK. Receptor mediated tumor targeting: an emerging approach for cancer therapy. Curr Drug Deliv. 2011 Jan;8(1):45–58.CrossRefGoogle ScholarPubMed
Olafsen, T, Betting D, Kenanova VE, Salazar FB, Clarke P, Said J, et al. Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. J Nucl Med. 2009 Sep;50(9):1500–8.CrossRefGoogle ScholarPubMed
Pool, SE, Krenning EP, Koning GA, van Eijck CH, Teunissen JJ, Kam B, et al. Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin Nucl Med. 2010 May;40(3):209–18.CrossRefGoogle ScholarPubMed
Smith, AL, Freeman, SM, Stehouwer, JS, Inoue, K, Voll, RJ, Young, LJ, et al. Synthesis and evaluation of C-11, F-18 and I-125 small molecule radioligands for detecting oxytocin receptors. Bioorg Med Chem. 2012 Apr 15;20(8):2721–38.CrossRefGoogle ScholarPubMed
Soontornworajit, B, Wang, Y. Nucleic acid aptamers for clinical diagnosis: cell detection and molecular imaging. Anal Bioanal Chem. 2011 Feb;399(4):1591–9.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats No formats are currently available for this content.
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats No formats are currently available for this content.
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats No formats are currently available for this content.
×